Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn ’s Disease in Italy
ConclusionThis analysis, carried-out in an Italian clinical setting, may help to optimise therapy for patients with UC and CD and provide relevant clinical practice data to inform decision-makers. (Source: Advances in Therapy)
Source: Advances in Therapy - April 15, 2024 Category: Drugs & Pharmacology Source Type: research
Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review
ConclusionRAM + PTX as a second-line treatment is effective and associated with an acceptable toxicity profile in patients with advanced or metastatic G/GEA in real-world settings of Japan and South Korea. More studies are recommended to further evaluate effectiveness and safety of RAM or RAM-based therapy, especially after anti-PD-1 therapy, in a wider Eastern Asian population.Trial RegistrationINPLASY registration number INPLASY2022120023. (Source: Advances in Therapy)
Source: Advances in Therapy - April 15, 2024 Category: Drugs & Pharmacology Source Type: research
Reduction in Diabetes-Related Hospitalizations and Medical Costs After Dexcom G6 Continuous Glucose Monitor Initiation in People with Type 2 Diabetes Using Intensive Insulin Therapy
ConclusionInitiation of Dexcom G6 among people with T2D using intensive insulin therapy was associated with a significant reduction in diabetes-related ED and inpatient visits and related HCRU costs. Expanded use of RT-CGM could augment these benefits and result in further cost reductions. (Source: Advances in Therapy)
Source: Advances in Therapy - April 15, 2024 Category: Drugs & Pharmacology Source Type: research
Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea
ConclusionsThis real-world study suggests that TFI is a meaningful surrogate measure of treatment effectiveness in IBS-D. Patients treated with rifaximin had longer treatment-free periods and lower healthcare costs than patients treated with eluxadoline. (Source: Advances in Therapy)
Source: Advances in Therapy - April 15, 2024 Category: Drugs & Pharmacology Source Type: research
Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A
ConclusionsPS-adjusted analyses were consistent with prior intra-individual comparisons. Compared with participants receiving prophylactic FVIII, the participants receiving valoctocogene roxaparvovec experienced lower ABR, and a higher proportion had zero bleeds.Trail RegistrationClinicalTrials.gov identifier, NCT03370913. (Source: Advances in Therapy)
Source: Advances in Therapy - April 15, 2024 Category: Drugs & Pharmacology Source Type: research
Rationale and Design of the IMPROVE Trial: A Multicenter, Randomized, Controlled, Open-label, Blinded-endpoint Trial Assessing the Efficacy of Remote Ischemic Conditioning in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting
AbstractIntroductionDespite the appearance of off-pump coronary artery bypass grafting (CABG), ischemia –reperfusion injury (IRI) in the perioperative period still arouses concerns of clinicians. Remote ischemic conditioning (RIC) is the process of repeated ischemia and reperfusion in the peripheral vessels, which is proven to reduce IRI in vital organs. However, the effect of RIC in patients underg oing off-pump CABG is still unclear.MethodsThis IMPROVE trial is a national, multicenter, randomized, controlled, open-label, blinded-endpoint clinical trial designed to assess whether RIC intervention can improve short-term ...
Source: Advances in Therapy - April 15, 2024 Category: Drugs & Pharmacology Source Type: research
Correction to: Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis
(Source: Advances in Therapy)
Source: Advances in Therapy - April 10, 2024 Category: Drugs & Pharmacology Source Type: research
Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research
ConclusionOverall, the findings from this study provide evidence for the content validity of the UWDRS Part II and supportive evidence for the content validity of Part III. The UWDRS should be used in conjunction with additional clinical outcomes assessments, specifically those evaluating the hepatic and psychiatric signs/symptoms of WD, to provide a comprehensive evaluation of the WD patient experienc e. (Source: Advances in Therapy)
Source: Advances in Therapy - April 4, 2024 Category: Drugs & Pharmacology Source Type: research
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study
ConclusionPegcetacoplan sustained long-term improvements in hemoglobin concentrations, fatigue reduction, and transfusion burden. Long-term safety findings corroborate the favorable profile established for pegcetacoplan.Trial RegistrationClinicalTrials.gov identifier, NCT03531255. (Source: Advances in Therapy)
Source: Advances in Therapy - April 4, 2024 Category: Drugs & Pharmacology Source Type: research
Perceptions and Experiences of People with Obesity and Type 2 Diabetes Around Appetite and Eating Behaviors: A Qualitative Study
ConclusionThe findings build upon existing models of factors influencing food choices. Findings confirm prior research regarding impact of drivers/triggers on food choice in people with obesity and T2D and indicate underlying disease state does not appear to influence eating behaviors in people with stable body weight. (Source: Advances in Therapy)
Source: Advances in Therapy - April 1, 2024 Category: Drugs & Pharmacology Source Type: research
Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy
AbstractDuchenne muscular dystrophy (DMD) is one of the most prevalent X-linked inherited neuromuscular disorders, with an estimated incidence between 1 in 3500 and 5000 live male births. The median life expectancy at birth is around 30 years due to a rapid and severe disease progression. Currently, there is no cure for DMD, and the standard of care is mainly palliative therapy and glucocorticoids to mitigate symptoms and improve quality of life. Recent advances in phosphorodiamidate morpholino antisense oligonucleotide (PMO) tec hnology has proven optimistic in providing a disease-modifying therapy rather than a palliat...
Source: Advances in Therapy - March 24, 2024 Category: Drugs & Pharmacology Source Type: research
Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives
The objective of this article is to describe the perspectives of five caregivers of girls in trofinetide clinical trials as well as those of three nurse trial coordinators, with a focus on management of GI symptoms of trofinetide treatment.Audio Abstract available for this article.Audio Abstract: Jane Lane provides an overview and discusses key findings of the article titled “Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives.” (MP4 83274 KB) (Source: Advances in Therapy)
Source: Advances in Therapy - March 24, 2024 Category: Drugs & Pharmacology Source Type: research
Selective Internal Radiation Therapy Using Y-90 Resin Microspheres for Metastatic Colorectal Cancer: An Updated Systematic Review and Network Meta-Analysis
ConclusionCurrent evidence supports SIRT treatment in patients with chemotherapy-refractory or chemotherapy-intolerant mCRC compared to newer oral agents, with comparable OS and low incidence of AEs. (Source: Advances in Therapy)
Source: Advances in Therapy - March 24, 2024 Category: Drugs & Pharmacology Source Type: research
Correction to: Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia
(Source: Advances in Therapy)
Source: Advances in Therapy - March 24, 2024 Category: Drugs & Pharmacology Source Type: research
Correction to: Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients ’ Real-World Insights for Optimizing Outcomes
(Source: Advances in Therapy)
Source: Advances in Therapy - March 24, 2024 Category: Drugs & Pharmacology Source Type: research
